Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
→ Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. On April 1, 2027, the Japanese pharma will split the commercialization efforts ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.